Temporal and Spatial Topography of Cell Proliferation in Cancer
Overview
Authors
Affiliations
Proliferation is a fundamental trait of cancer cells, but its properties and spatial organization in tumours are poorly characterized. Here we use highly multiplexed tissue imaging to perform single-cell quantification of cell cycle regulators and then develop robust, multivariate, proliferation metrics. Across diverse cancers, proliferative architecture is organized at two spatial scales: large domains, and smaller niches enriched for specific immune lineages. Some tumour cells express cell cycle regulators in the (canonical) patterns expected of freely growing cells, a phenomenon we refer to as 'cell cycle coherence'. By contrast, the cell cycles of other tumour cell populations are skewed towards specific phases or exhibit non-canonical (incoherent) marker combinations. Coherence varies across space, with changes in oncogene activity and therapeutic intervention, and is associated with aggressive tumour behaviour. Thus, multivariate measures from high-plex tissue images capture clinically significant features of cancer proliferation, a fundamental step in enabling more precise use of anti-cancer therapies.
Molecular principles underlying aggressive cancers.
Nussinov R, Yavuz B, Jang H Signal Transduct Target Ther. 2025; 10(1):42.
PMID: 39956859 PMC: 11830828. DOI: 10.1038/s41392-025-02129-7.
Quality control for single-cell analysis of high-plex tissue profiles using CyLinter.
Baker G, Novikov E, Zhao Z, Vallius T, Davis J, Lin J Nat Methods. 2024; 21(12):2248-2259.
PMID: 39478175 PMC: 11621021. DOI: 10.1038/s41592-024-02328-0.
Gao Y, Feder A bioRxiv. 2024; .
PMID: 39005367 PMC: 11244928. DOI: 10.1101/2024.06.27.601073.
Wang H, Wang Y, Mirjavadi S, Andersen T, Moldovan L, Vatankhah P Nat Commun. 2024; 15(1):5521.
PMID: 38951553 PMC: 11217425. DOI: 10.1038/s41467-024-49833-6.
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer.
Grinshpun A, Russo D, Ma W, Verma A, Hermida-Prado F, Sherman S NPJ Breast Cancer. 2024; 10(1):42.
PMID: 38851818 PMC: 11162492. DOI: 10.1038/s41523-024-00647-1.